title: Cervical cancer prevention: immunization and screening 2015.
abstract: Both primary and secondary prevention of cervical cancer are now available. Immunizations against human papillomavirus (HPV) types 16 and 18 have the potential to prevent 70% of cancers of the cervix plus a large percentage of other lower anogenital tract cancers. Screening guidelines were recently changed to recommend cotesting with cytology plus an HPV test. The addition of HPV testing increases the sensitivity and negative predictive value of screening over the Papanicolaou (Pap) test alone.
authors.affiliation: Department of Obstetrics and Gynecology, 1 University of New Mexico, MSC 10 5580, Albuquerque, NM 87131, USA.
authors.forename: Lauren
authors.initials: L
authors.lastname: Thaxton
authors.affiliation: Department of Obstetrics and Gynecology, 1 University of New Mexico, MSC 10 5580, Albuquerque, NM 87131, USA. Electronic address: awaxman@salud.unm.edu.
authors.forename: Alan G
authors.initials: AG
authors.lastname: Waxman
mesh_terms: D005260:Female; D006801:Humans; D007114:Immunization; D008403:Mass Screening / Q000379:methods*; D027383:Papillomaviridae / Q000276:immunology; D030361:Papillomavirus Infections / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines
keywords: Cervical cancer screening; Cytology; HPV vaccine; Human papillomavirus